Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571)
Sponsor: Astex Pharmaceuticals, Inc.
A PHASE2 clinical study on Chronic Myelogenous Leukemia, this trial is completed. The trial is conducted by Astex Pharmaceuticals, Inc. and has accumulated 7 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astex Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .